← All trials
NCT03816397
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 31, 2019
- Primary completion
- Jun 30, 2022
- Completion date
- Feb 28, 2023
- First posted
- —
- Last posted
- —
- Enrollment
- 118
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of California, San FranciscoLead sponsor
- National Eye Institute (NEI)Collaborator
- University Hospitals Bristol NHS Foundation TrustCollaborator
- University of PennsylvaniaCollaborator
- University of LondonCollaborator
- Newcastle UniversityCollaborator
- Sheffield Hallam UniversityCollaborator
- University of East AngliaCollaborator
- University of KansasCollaborator
- University of LeicesterCollaborator
- University of LiverpoolCollaborator
- University of ManchesterCollaborator
- University of MelbourneCollaborator
- University of MiamiCollaborator
- University of California, DavisCollaborator
- University of California, San FranciscoSponsor investigator
- University of CambridgeCollaborator
- University of CincinnatiCollaborator
- University of UtahCollaborator
- Vanderbilt UniversityCollaborator
- University of Texas, AustinCollaborator
- Colorado Retina AssociatesCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.